Could a hedgehog blocker tame rare bone cancer?
NCT ID NCT01267955
First seen Mar 08, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This phase 2 trial tests the drug vismodegib in 45 people with advanced chondrosarcoma, a rare bone cancer that has spread and is hard to treat. Vismodegib works by blocking a growth signal in cancer cells. The study looks at how many patients have their tumors shrink or stay stable for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEDIFFERENTIATED CHONDROSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Leon Berard
Lyon, 69373, France
-
Centre Oscar Lambert
Lille, 59020, France
-
Gustave Roussy
Villejuif, 94805, France
-
Hopital De La Timone
Marseille, 13385, France
-
Institut Bergonie Cancer Center
Bordeaux, 33076, France
-
Institut Curie Paris
Paris, 75005, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vismodegib (Erivedge)
What this could lead to
If successful, this could point toward a treatment option for advanced chondrosarcoma, a rare bone cancer with few effective therapies.
What could go wrong
This is a small, early-phase trial with only 45 participants. The drug may not shrink tumors or improve survival, and side effects like muscle spasms, hair loss, and fatigue are common.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.